Caprylic acid attenuates amyloid-β proteotoxicity by supplying energy via β-oxidation in an Alzheimer’s disease model of the nematode Caenorhabditis elegans

References

• Querfurth HW, LaFerla FM. Alzheimer’s disease. New Engl J Med. 2010;362(4):329–44. doi:10.1056/NEJMra0909142.
   PubMed Web of Science ®Google Scholar
• Pagani L, Eckert A. Amyloid-beta interaction with mitochondria. Intern J Alzheimer's Dis. 2011;2011:1–12. doi:10.4061/2011/925050.
   Google Scholar
• Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609–33. doi:10.1038/s41573-020-0072-x.
   PubMed Web of Science ®Google Scholar
• Müller WE, Eckert A, Kurz C, Eckert GP, Leuner K. Mitochondrial dysfunction: Common final pathway in brain aging and Alzheimer’s disease-therapeutic aspects. Mol Neurobiol. 2010;41(2–3):159–71. doi:10.1007/s12035-010-8141-5.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimer's Dis. 2018;62(3):1403–16. doi:10.3233/JAD-170585.
   PubMed Web of Science ®Google Scholar
• Marten B, Pfeuffer M, Schrezenmeir J. Medium-chain triglycerides. Intern Dairy J. 2006;16(11):1374–82. doi:10.1016/j.idairyj.2006.06.015.
   Web of Science ®Google Scholar
• Bach AC, Babayan VK. Medium-chain triglycerides: an update. Amer J Clin Nutr. 1982;36:950–62. doi:10.1093/ajcn/36.5.950.
   PubMed Web of Science ®Google Scholar
• Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid biosynthesis defects. J Inher Metab Dis. 2014;37(4):553–63. doi:10.1007/s10545-014-9705-8.
   PubMed Web of Science ®Google Scholar
• Newman JC, Verdin E. β-Hydroxybutyrate: A signaling metabolite. Annu Rev Nutr. 2017;37(1):51–76. doi:10.1146/annurev-nutr-071816-064916.
   PubMedGoogle Scholar
• dos Santos SM, Romeiro CFR, Rodrigues CA, Cerqueira ARL, Monteiro MC. Mitochondrial dysfunction and alpha-lipoic acid: Beneficial or harmful in Alzheimer’s disease? Oxid Med Cell Longev. 2019;2019; doi:10.1155/2019/8409329.
   Web of Science ®Google Scholar
• McColl G, Roberts BR, Pukala TL, Kenche VB, Roberts CM, Link CD, et al. Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease. Mol Neurodegener. 2012;7(57). doi:10.1186/1750-1326-7-57.
   PubMedGoogle Scholar
• Stiernagle, T. (2006). Maintenance of C. elegans, WormBook: the online review of C. elegans biology. doi:10.1895/wormbook.1.101.1
   Google Scholar
• Corsi AK. A Biochemist’s Guide to C. elegans. Anal Biochem. 2006;1(359):1–17. doi:10.1016/j.ab.2006.07.033.
   Google Scholar
• Perni M, Challa PK, Kirkegaard JB, Limbocker R, Koopman M, Hardenberg MC, et al. Massively parallel C. elegans tracking provides multi-dimensional fingerprints for phenotypic discovery. J Neurosci Meth. 2018;306:57–67. doi:10.1016/j.jneumeth.2018.02.005.
   PubMed Web of Science ®Google Scholar
• Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene. 2001;263:103–12. doi:10.1016/S0378-1119(00)00579-5.
   PubMed Web of Science ®Google Scholar
• Lehner B, Tischler J, Fraser AG. RNAi screens in Caenorhabditis elegans in a 96-well liquid format and their application to the systematic identification of genetic interactions. Nat Protoc. 2006;1(3):1617–20. doi:10.1038/nprot.2006.245.
   PubMed Web of Science ®Google Scholar
• Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - A new method based on robust nonlinear regression and the false discovery rate. BMC Bioinform. 2006;7:1–20. doi:10.1186/1471-2105-7-123.
   PubMed Web of Science ®Google Scholar
• Croteau E, Castellano CA, Richard MA, Fortier M, Nugent S, Lepage M, et al. Ketogenic medium chain triglycerides increase brain energy metabolism in Alzheimer’s disease. J Alzheim Dis. 2018;64(2):551–61. doi:10.3233/JAD-180202.
   PubMed Web of Science ®Google Scholar
• Fortier M, Castellano CA, Croteau E, Langlois F, Bocti C, St-Pierre V, et al. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimer’s Dementia. 2019;15(5):625–34. doi:10.1016/j.jalz.2018.12.017.
   PubMed Web of Science ®Google Scholar
• Ota M, Matsuo J, Ishida I, Takano H, Yokoi Y, Hori H, et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer’s disease. Neurosci Lett. 2019;690(October 2018):232–6. doi:10.1016/j.neulet.2018.10.048.
   PubMedGoogle Scholar
• Edwards C, Canfield J, Copes N, Rehan M, Lipps D, Bradshaw PC. D-beta-hydroxybutyrate extends lifespan in C. elegans. Aging. 2014;6(8):621–44. doi:10.18632/aging.100683.
   PubMedGoogle Scholar
• Spector R. Fatty acid transport through the blood-brain barrier. J Neurochem. 1988;50(2):639–43. doi:10.1111/j.1471-4159.1988.tb02958.x.
   PubMed Web of Science ®Google Scholar
• Wlaź P, Socała K, Nieoczym D, Łuszczki JJ, Arnowska I, Arnowski T, et al. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology. 2012;62(4):1882–9. doi:10.1016/j.neuropharm.2011.12.015.
   PubMed Web of Science ®Google Scholar
• Haynes VR, Michael NJ, van den Top M, Zhao FY, Brown RD, de Souza D, et al. A Neural basis for Octanoic acid regulation of energy balance. Mol Metab. 2020;34(January):54–71. doi:10.1016/j.molmet.2020.01.002.
   PubMedGoogle Scholar
• Yang SY, He XY, Schulz H. Fatty acid oxidation in rat brain is limited by the low activity of 3-ketoacyl-coenzyme A thiolase. J Biol Chem. 1987;262(27):13027–32. doi:10.1016/S0021-9258(18)45161-7.
   PubMed Web of Science ®Google Scholar
• Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inher Metab Dis. 2010;33(5):469–77. doi:10.1007/s10545-010-9061-2.
   PubMed Web of Science ®Google Scholar
• Reichmann H, Maltese WA, DeVivo DC. Enzymes of fatty acid β-oxidation in developing brain. J Neurochem. 1988;51(2):339–44. doi:10.1111/j.1471-4159.1988.tb01044.x.
   PubMed Web of Science ®Google Scholar
• Khabbush A, Orford M, Tsai YC, Rutherford T, O’Donnell M, Eaton S, Heales SJR. Neuronal decanoic acid oxidation is markedly lower than that of octanoic acid: A mechanistic insight into the medium-chain triglyceride ketogenic diet. Epilepsia. 2017;58(8):1423–9. doi:10.1111/epi.13833.
   PubMed Web of Science ®Google Scholar
• Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci. 2003;23(13):5928–35. doi:10.1523/JNEUROSCI.23-13-05928.2003.
   PubMed Web of Science ®Google Scholar
• Arranz AM, de Strooper B. The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18(4):406–14. doi:10.1016/S1474-4422(18)30490-3.
   PubMed Web of Science ®Google Scholar
• Nanclares C, Baraibar AM, Araque A, Kofuji P. Dysregulation of astrocyte–neuronal communication in Alzheimer’s disease. Intern J Mol Sci. 2021;22(15):7887. doi:10.3390/ijms22157887.
   PubMed Web of Science ®Google Scholar
• Panov A, Orynbayeva Z, Vavilin V, Lyakhovich V. Fatty acids in energy metabolism of the central nervous system. BioMed Res Intern. 2014;2014:1–22. doi:10.1155/2014/472459.
   Web of Science ®Google Scholar
• Thevenet J, de Marchi U, Domingo JS, Christinat N, Bultot L, Lefebvre G, et al. Medium-chain fatty acids inhibit mitochondrial metabolism in astrocytes promoting astrocyte-neuron lactate and ketone body shuttle systems. FASEB J. 2016;30(5):1913–26. doi:10.1096/fj.201500182.
   PubMed Web of Science ®Google Scholar